{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:01:44Z","timestamp":1790013704290,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113197","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T03:41:24Z","timestamp":1726717284000},"page":"113197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"PB","title":["Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer"],"prefix":"10.1016","volume":"142","author":[{"given":"Yafeng","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-3439","authenticated-orcid":false,"given":"Hongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/lary.24915","article-title":"Survival trends in hypopharyngeal cancer: a population-based review","volume":"125","author":"Newman","year":"2015","journal-title":"Laryngoscope."},{"issue":"5","key":"10.1016\/j.intimp.2024.113197_b0020","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/lary.29857","article-title":"Health-Related Quality of Life, Dysphagia, Voice Problems, Depression, and Anxiety After Total Laryngectomy","volume":"132","author":"Wulff","year":"2022","journal-title":"Laryngoscope."},{"key":"10.1016\/j.intimp.2024.113197_b0025","unstructured":"Sanders O, Pathak S. Hypopharyngeal Cancer. StatPearls. Treasure Island (FL)2023."},{"issue":"16","key":"10.1016\/j.intimp.2024.113197_b0030","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1002\/cam4.6354","article-title":"Induction chemotherapy-based organ-preservation protocol improve the function preservation compared with immediate total laryngectomy for locally advanced hypopharyngeal cancer-Results of a matched-pair analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2024.113197_b0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijsu.2020.04.059","article-title":"Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis","volume":"82","author":"Cui","year":"2020","journal-title":"Int J Surg."},{"issue":"6","key":"10.1016\/j.intimp.2024.113197_b0040","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1245\/s10434-016-5088-4","article-title":"Comparison of Oncological and Functional Outcomes between Initial Surgical versus Non-Surgical Treatments for Hypopharyngeal Cancer","volume":"23","author":"Jang","year":"2016","journal-title":"Ann Surg Oncol."},{"issue":"22","key":"10.1016\/j.intimp.2024.113197_b0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.113197_b0050","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00405-010-1274-3","article-title":"Salvage surgery for local recurrence after chemoradiotherapy or radiotherapy in hypopharyngeal cancer patients","volume":"267","author":"Taki","year":"2010","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113197_b0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.trecan.2019.02.007","article-title":"Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy","volume":"5","author":"Horton","year":"2019","journal-title":"Trends Cancer."},{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030672","article-title":"Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer","volume":"15","author":"Rao","year":"2023","journal-title":"Cancers (basel)."},{"key":"10.1016\/j.intimp.2024.113197_b0065","doi-asserted-by":"crossref","first-page":"1160144","DOI":"10.3389\/fonc.2023.1160144","article-title":"Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent\/metastatic head and neck squamous cell carcinoma","volume":"13","author":"Black","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2024.113197_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102829","article-title":"Immunotherapy in head and neck cancer: The great challenge of patient selection","volume":"144","author":"Napolitano","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.intimp.2024.113197_b0075","article-title":"Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges","volume":"10","author":"Qian","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2024.113197_b0080","doi-asserted-by":"crossref","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28.","DOI":"10.1016\/S0140-6736(19)32591-7"},{"issue":"21","key":"10.1016\/j.intimp.2024.113197_b0085","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.19.03156","article-title":"Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study","volume":"38","author":"Powell","year":"2020","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113197_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00262-023-03579-0","article-title":"Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma","volume":"73","author":"Peng","year":"2024","journal-title":"Cancer Immunol Immunother."},{"issue":"12","key":"10.1016\/j.intimp.2024.113197_b0100","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1007\/s00262-023-03550-z","article-title":"PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study","volume":"72","author":"Fang","year":"2023","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2024.113197_b0105","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2024.113197_b0110","unstructured":"Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial.pdf."},{"key":"10.1016\/j.intimp.2024.113197_b0115","doi-asserted-by":"crossref","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(7):873-98.","DOI":"10.6004\/jnccn.2020.0031"},{"issue":"8","key":"10.1016\/j.intimp.2024.113197_b0120","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.intimp.2024.113197_b0125","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2019.06.015","article-title":"Induction chemotherapy in head and neck cancers: Results and controversies","volume":"95","author":"Gau","year":"2019","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113197_b0130","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hed.27119","article-title":"Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma","volume":"44","author":"Li","year":"2022","journal-title":"Head Neck."},{"key":"10.1016\/j.intimp.2024.113197_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105470","article-title":"Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB","volume":"121","author":"Hochfelder","year":"2021","journal-title":"Oral Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113197_b0140","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/jso.26440","article-title":"Survival and complications with a surgical approach in advanced hypopharyngeal cancer","volume":"123","author":"Galeano Machuca","year":"2021","journal-title":"J Surg Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113197_b0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12957-020-01866-z","article-title":"Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma","volume":"18","author":"Tsai","year":"2020","journal-title":"World J Surg Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113197_b0150","first-page":"1735","article-title":"Prognostic factor of severe complications in patients with hypopharyngeal cancer with primary concurrent chemoradiotherapy","volume":"35","author":"Chen","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113197_b0155","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1186\/s12885-022-10306-y","article-title":"Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer."},{"issue":"9","key":"10.1016\/j.intimp.2024.113197_b0160","first-page":"2794","article-title":"Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis","volume":"109","author":"Chen","year":"2023","journal-title":"Int J Surg."},{"key":"10.1016\/j.intimp.2024.113197_b0165","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2147\/CMAR.S358620","article-title":"The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study","volume":"14","author":"Yin","year":"2022","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.intimp.2024.113197_b0170","doi-asserted-by":"crossref","first-page":"1145303","DOI":"10.3389\/fonc.2023.1145303","article-title":"Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study","volume":"13","author":"Fei","year":"2023","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113197_b0175","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","article-title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II","volume":"29","author":"Dietz","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.intimp.2024.113197_b0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.07.001","article-title":"nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma","volume":"72","author":"Adkins","year":"2017","journal-title":"Oral Oncol."},{"key":"10.1016\/j.intimp.2024.113197_b0185","doi-asserted-by":"crossref","first-page":"1282629","DOI":"10.3389\/fimmu.2023.1282629","article-title":"Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113197_b0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4149\/neo_2018_170213N102","article-title":"Value of two-cycle docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy in hypopharyngeal carcinoma","volume":"65","author":"Luo","year":"2018","journal-title":"Neoplasma."},{"issue":"1","key":"10.1016\/j.intimp.2024.113197_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00405-017-4766-6","article-title":"Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands","volume":"275","author":"Petersen","year":"2018","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113197_b0200","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2024.113197_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102644","article-title":"Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy","volume":"121","author":"Smussi","year":"2023","journal-title":"Cancer Treat Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924017193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924017193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:59:51Z","timestamp":1734069591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924017193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"alternative-id":["S1567576924017193"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113197","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113197"}}